Bradley M Lunde from Grantham, NH, age 45

Anti-Cd19 Antibodies And Multi-Specific Binding Proteins
view source
US Patent:

20230037815, Feb 9, 2023
Filed:

Dec 11, 2020
Appl. No.:

17/784988
Inventors:

- Cambridge MA, US
Jennifer Michaelson - Cambridge MA, US
Bochong Li - Boston MA, US
Naveen Mehta - Cambridge MA, US
Jonathan Belk - Lebanon NH, US
Nathan Sharkey - Lebanon NH, US
Bianka Prinz - Lebanon NH, US
Bradley M. Lunde - Lebanon NH, US
Nga Rewa Houston - Lebanon NH, US
International Classification:

C07K 16/28
A61P 31/04
Abstract:

Provided herein are anti-CD 19 antibodies and multi-specific binding proteins that bind CD 19, CD3, and serum albumin. Also provided are pharmaceutical compositions comprising these antibodies or multi-specific binding proteins, expression vectors and host cells for making these antibodies or multi-specific binding proteins, and methods of use of these antibodies or multi-specific binding proteins in treating cancers.

Anti-Serum Albumin Antibodies
view source
US Patent:

20230032087, Feb 2, 2023
Filed:

Dec 11, 2020
Appl. No.:

17/785011
Inventors:

- Cambridge MA, US
Jennifer Michaelson - Cambridge MA, US
Bochong Li - Boston MA, US
Naveen Mehta - Cambridge MA, US
Bianka Prinz - Lebanon NH, US
Bradley M. Lunde - Lebanon NH, US
Nga Rewa Houston - Lebanon NH, US
International Classification:

C07K 16/28
C07K 16/46
Abstract:

The invention relates to anti-serum albumin antibodies and multi-specific binding proteins comprising the same. The invention also relates to pharmaceutical compositions comprising the antibodies or multi-specific binding proteins, expression vectors and host cells for making the antibodies or multi-specific binding proteins, and methods of use of the antibodies or multi-specific binding proteins in treatment of diseases or disorders.

Protein Binding Nkg2D, Cd16 And A Fibroblast Activation Protein
view source
US Patent:

20210363261, Nov 25, 2021
Filed:

May 16, 2019
Appl. No.:

17/055792
Inventors:

- Waltham MA, US
Ann F. Cheung - Lincoln MA, US
Jinyan Du - Waltham MA, US
Asya Grinberg - Lexington MA, US
William Haney - Wayland MA, US
Nicolai Wagtmann - Concord MA, US
Bradley M. Lunde - Lebanon NH, US
Bianka Prinz - Lebanon NH, US
International Classification:

C07K 16/28
C07K 16/40
C07K 16/46
Abstract:

Multi-specific binding proteins that bind NKG2D receptor, CD16, and fibroblast activation protein (FAP) are described, as well as pharmaceutical compositions and therapeutic methods of the multi-specific binding proteins useful for the treatment of cancer, autoimmune disease, or fibrosis.

Multi-Specific Binding Proteins That Bind Bcma, Nkg2D And Cd16, And Methods Of Use
view source
US Patent:

20210317223, Oct 14, 2021
Filed:

Aug 8, 2019
Appl. No.:

17/266349
Inventors:

- Waltham MA, US
Gregory P. Chang - Medford MA, US
Ann F. Cheung - Lincoln MA, US
Asya Grinberg - Lexington MA, US
William Haney - Wayland MA, US
Nicolai Wagtmann - Concord MA, US
Bradley M. Lunde - Lebanon NH, US
Bianka Prinz - Lebanon NH, US
International Classification:

C07K 16/28
A61P 35/00
Abstract:

Multi-specific binding proteins that bind to and kill human cancer cells are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer. The cancer can be B-cell maturation antigen (BCMA)-expressing cancer. The multi-specific binding proteins provided herein exhibit high potency and maximum lysis of target cells compared to anti-BCMA monoclonal antibodies.

Proteins Binding Nkg2D, Cd16 And A Tumor-Associated Antigen
view source
US Patent:

20210292420, Sep 23, 2021
Filed:

Mar 2, 2021
Appl. No.:

17/190155
Inventors:

- Waltham MA, US
Ann F. Cheung - Lincoln MA, US
Asya Grinberg - Lexington MA, US
William Haney - Wayland MA, US
Bradley M. Lunde - Lebanon NH, US
Bianka Prinz - Lebanon NH, US
International Classification:

C07K 16/28
A61P 35/00
C07K 16/30
Abstract:

Multi-specific binding proteins that bind the NKG2D receptor, CD16, and a tumor-associated antigen are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

Proteins Binding Nkg2D, Cd16, And Egfr, Ccr4, Or Pd-L1
view source
US Patent:

20210261668, Aug 26, 2021
Filed:

Mar 1, 2021
Appl. No.:

17/188978
Inventors:

- Waltham MA, US
Ann F. Cheung - Lincoln MA, US
Jinyan Du - Waltham MA, US
Asya Grinberg - Lexington MA, US
William Haney - Wayland MA, US
Dhruv Kam Sethi - Belmont MA, US
Nicolai Wagtmann - Concord MA, US
Bradley M. Lunde - Lebanon NH, US
Bianka Prinz - Lebanon NH, US
International Classification:

C07K 16/28
A61P 35/00
Abstract:

Multi-specific binding proteins that bind NKG2D receptor, CD16, and a tumor-associated antigen selected from EGFR, HLA-E, CCR4, and PD-L1 are described, as well pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

Proteins Binding Nkg2D, Cd16 And P-Cadherin
view source
US Patent:

20210238290, Aug 5, 2021
Filed:

May 6, 2019
Appl. No.:

17/053558
Inventors:

- Waltham MA, US
Ann F. Cheung - Lincoln MA, US
Jinyan Du - Waltham MA, US
Asya Grinberg - Lexington MA, US
William Haney - Wayland MA, US
Bradley M. Lunde - Lebanon NH, US
Bianka Prinz - Lebanon NH, US
International Classification:

C07K 16/28
A61P 35/00
Abstract:

Multi-specific binding proteins that bind NKG2D receptor, CD16, and P-cadherin, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

Proteins Binding Nkg2D, Cd16 And An Antigen Associated With Tumors, Mdscs And/Or Tams
view source
US Patent:

20210221894, Jul 22, 2021
Filed:

Apr 3, 2019
Appl. No.:

17/045016
Inventors:

- Waltham MA, US
Gregory P. Chang - Medford MA, US
Ann F. Cheung - Lincoln MA, US
Jean-Marie Cuillerot - Somerville MA, US
Jinyan Du - Waltham MA, US
Asya Grinberg - Lexington MA, US
William Haney - Wayland MA, US
Steven O'Neil - Wayland MA, US
Nicolai Wagtmann - Concord MA, US
Bradley M. Lunde - Lebanon NH, US
Bianka Prinz - Lebanon NH, US
International Classification:

C07K 16/28
A61P 35/00
Abstract:

Multi-specific binding proteins that bind the NKG2D receptor, CD 16, and a tumor-associated antigen on tumor cells, or an antigen on myeloid-derived suppressor cells or tumor-associated macrophages are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.